Copper for Connective Tissue

Table of Contents

1. Lysyl Oxidase — the Copper-Dependent Cross-Linker
2. Collagen Cross-Linking — Tensile Strength
3. Elastin Cross-Linking — Desmosine and Isodesmosine
4. Aortic Aneurysm and Spontaneous Dissection
5. Menkes Disease — the Genetic Proof
6. Occipital Horn Syndrome (Mild Menkes)
7. Bone Fragility and Cortical Thinning
8. Skin Elasticity, Pili Torti, and Wound Healing
9. Acquired Vascular Risk in Adults
10. Topical Copper Peptides (GHK-Cu) for Skin
11. Key Research Papers
12. Connections
13. Featured Videos

Lysyl Oxidase — the Copper-Dependent Cross-Linker

Lysyl oxidase (LOX, EC 1.4.3.13) is a 32-kilodalton extracellular copper-containing enzyme that catalyzes the oxidative deamination of peptidyl lysine and hydroxylysine residues in collagen and elastin. The reaction is:

peptidyl-lysine + O&sub2; + H&sub2;O → peptidyl-allysine + NH&sub3; + H&sub2;O&sub2;

The peptidyl-allysine product is a reactive aldehyde that spontaneously condenses with other allysines (or with unmodified lysines) on adjacent collagen or elastin chains to form Schiff-base and aldol cross-links. These cross-links are what convert the soluble monomeric precursors (tropocollagen, tropoelastin) into the insoluble cross-linked fibrils and fibers that give connective tissue its mechanical properties.

LOX is synthesized as a 50-kDa proenzyme by fibroblasts, smooth muscle cells, chondrocytes, and other matrix-producing cells. It is secreted into the extracellular space and proteolytically activated by bone morphogenetic protein 1 (BMP-1), which removes an N-terminal propeptide to release the active 32-kDa mature enzyme. The mature enzyme contains one copper atom per molecule plus a covalently bound cofactor called lysyl tyrosylquinone (LTQ), which is formed by intramolecular cross-linking of a copper-coordinated lysine and a tyrosine residue in the enzyme itself. Both the copper atom and the LTQ cofactor are essential for catalysis — remove either and the enzyme is inactive.

The copper-loading step happens in the late secretory pathway through the copper-transporting ATPase ATP7A. Loss-of-function mutations in ATP7A — the cause of Menkes disease — therefore produce a phenotype that includes severe lysyl oxidase deficiency on top of the systemic copper deficiency, because the enzyme is synthesized and secreted as the inactive copper-free apoprotein.

There are five LOX-family members in humans: LOX itself plus LOXL1, LOXL2, LOXL3, and LOXL4. Each performs similar oxidative chemistry on different connective-tissue substrates in different tissues, and all are copper-dependent. LOXL1 deficiency is associated with pelvic organ prolapse and pseudoexfoliation glaucoma; LOX deficiency is the dominant contributor to aortic and skin pathology.

Back to Table of Contents

Collagen Cross-Linking — Tensile Strength

Collagen is the most abundant protein in the body (approximately 30% of total body protein) and the primary tensile-load-bearing protein in skin, bone, tendon, ligament, cartilage, and the dermis. It is synthesized as procollagen by fibroblasts, secreted into the extracellular space, proteolytically processed to tropocollagen, and assembled into the staggered quarter-stagger array that produces collagen fibrils with their characteristic 67-nanometer banding pattern. The fibrils gain their tensile strength from intermolecular covalent cross-links introduced by lysyl oxidase.

The cross-linking chemistry begins with LOX oxidation of specific lysine and hydroxylysine residues in the N- and C-terminal telopeptide regions of tropocollagen. The resulting aldehydes (allysine and hydroxyallysine) then participate in spontaneous, non-enzymatic condensation reactions to form first immature divalent cross-links (such as hydroxylysinonorleucine and dehydrohydroxylysinonorleucine), then mature trivalent cross-links (pyridinoline and deoxypyridinoline) over weeks to months. The mature trivalent cross-links are the most mechanically important and the slowest to form.

Without lysyl oxidase, this cross-linking does not occur. The tropocollagen monomers do assemble into fibrils, but they are mechanically weak. Skin in copper deficiency becomes thinner, more easily torn, and slower to heal. Tendons and ligaments lose tensile strength. The wound-healing defect is particularly important in surgical and burn patients with marginal copper status.

Back to Table of Contents

Elastin Cross-Linking — Desmosine and Isodesmosine

Elastin is the second great fibrous protein of the connective tissue and the one that gives the aorta, lung, skin, and ligamentum flavum their elastic recoil. Where collagen resists tension, elastin stretches and then recoils elastically — the aortic wall, for example, must expand by about 10% with each systolic ejection and recoil during diastole, billions of times over a lifetime, without fatigue or failure.

The elastic-recoil property comes from elastin's unusual cross-linking architecture. Tropoelastin monomers are coiled into a hydrophobic, water-resistant rope-like structure and then cross-linked by lysyl oxidase. But where collagen cross-linking uses simple divalent or trivalent bonds, elastin uses tetravalent cross-links — desmosine and isodesmosine, which are pyridinium ring structures formed by the condensation of four lysine residues (three of which have been converted to allysine by LOX) on adjacent tropoelastin chains.

Desmosine and isodesmosine are unique to elastin — no other protein contains them. The tetravalent cross-linking creates a covalently bonded three-dimensional network that allows elastin to stretch and recoil without breaking or unraveling. The cross-link density is extremely high in tissues that must endure repeated mechanical strain: the aortic media, the elastic ligaments, and the elastic fibers of the lung.

Copper deficiency reduces lysyl oxidase activity and therefore reduces desmosine and isodesmosine formation. The result is "weakened" elastin — mechanically inadequate for the cyclic loading that healthy aortic wall and lung parenchyma must endure. Animal studies in copper-deficient pigs, rats, and chickens consistently show reduced elastin desmosine content along with arterial wall thinning, aneurysm formation, and skin laxity.

Back to Table of Contents

Aortic Aneurysm and Spontaneous Dissection

The most clinically dangerous manifestation of copper deficiency is failure of the aortic wall. The thoracic aorta, in particular, depends on intact elastin for its ability to absorb the systolic pulse pressure and recoil during diastole. When elastin cross-linking is inadequate, the aortic wall undergoes medial degeneration — loss of elastic lamellae, replacement by amorphous extracellular matrix, smooth muscle cell dropout, and ultimately frank dilation (aneurysm) or tearing (dissection).

The classic experimental demonstration came from studies of copper-deficient pigs in the 1960s and 1970s — the animals developed spontaneous aortic aneurysm and rupture, a phenotype that resolved with copper repletion. In copper-deficient chicks, the aorta held only one-half to two-thirds as much elastin as in chicks given enough copper, and tropoelastin (the uncross-linked building block) was at least 5 times higher than normal (Tinker 1986). A 1985 review by Tinker and Rucker summarises how copper and other nutrients govern the synthesis and cross-linking of connective-tissue proteins.

In humans, the genetic conditions that disrupt copper-dependent lysyl oxidase activity — Menkes disease and occipital horn syndrome (see below) — produce aortic aneurysm and arterial tortuosity as core features. Beyond these rare genetic conditions, acquired copper deficiency in adults has been implicated in some thoracic aortic aneurysm cases, though the evidence is more circumstantial than for the genetic conditions. The Lox knockout mouse (genetic deletion of LOX) dies perinatally from aortic and diaphragmatic rupture, providing rigorous proof that LOX activity is essential for vascular integrity.

These findings matter most for people with the acquired copper-deficiency risk factors (zinc overdose, bariatric surgery, prolonged TPN, severe malabsorption), and especially those with a first-degree family history of thoracic aortic aneurysm, dissection, or sudden cardiac death. Copper status is measured with blood copper and ceruloplasmin tests. The cardiac surgery and vascular medicine literature is still catching up to the recognition that nutritional copper deficiency is a real (though under-screened) modifiable risk factor for some aortic disease. Human evidence that nutritional copper deficiency causes aortic disease is still thin: the authors of a 2022 New Zealand pilot study (see Acquired Vascular Risk in Adults below) write that further studies are needed to establish cause and effect.

Back to Table of Contents

Menkes Disease — the Genetic Proof

Menkes disease (also called Menkes kinky hair syndrome) is the X-linked recessive disorder caused by loss-of-function mutations in ATP7A, the copper-transporting ATPase on the basolateral membrane of the enterocyte. ATP7A is required to export dietary copper from the enterocyte into the portal circulation, and a parallel ATP7A pool in the late secretory pathway of all cells delivers copper to the metalation step of cuproenzymes including lysyl oxidase, dopamine beta-hydroxylase, and tyrosinase.

Loss of ATP7A produces systemic copper deficiency from infancy — the affected boy (Menkes is X-linked, so virtually all clinically affected patients are male) absorbs copper into the enterocyte but cannot export it. Dietary copper accumulates in the gut wall and is shed with the enterocyte at the end of its lifespan, never reaching the rest of the body. The clinical phenotype emerges in the first months of life:

• "Kinky" or twisted hair (pili torti) — the pathognomonic finding, with hair that is sparse, lusterless, brittle, and microscopically shows twisting along the long axis. The disrupted hair cross-linking is the visible manifestation of LOX deficiency.
• Intractable seizures and developmental regression — from copper-dependent enzyme failures in the developing brain
• Hypothermia — from impaired norepinephrine synthesis (dopamine beta-hydroxylase is copper-dependent)
• Hypotonia and feeding difficulties
• Pale skin — from tyrosinase failure (tyrosinase is copper-dependent and is the rate-limiting enzyme of melanin synthesis)
• Aortic dilation, arterial tortuosity, and intracranial vascular abnormalities — the LOX-deficiency vascular phenotype
• Bladder diverticula and inguinal hernia — from extracellular matrix weakness
• Bone abnormalities — "Wormian bones" in the skull, metaphyseal flaring, and fragility
• Death typically by 3 years of age in untreated classical Menkes disease, usually from infection or vascular catastrophe

Treatment is copper given by injection under the skin, because people with Menkes disease cannot absorb copper from the gut. In a US National Institutes of Health study, 12 newborns picked up by a blood screening test and started on copper injections within 22 days of birth had 92% survival at a median follow-up of 4.6 years, compared with 13% at a median of 1.8 years in 15 children diagnosed and treated late. Only 2 of the 12 early-treated children had normal development and brain myelination; both had gene changes that left some ATP7A function working, and the authors note that newborns whose ATP7A function is not completely lost may respond best to early copper (Kaler 2008). In January 2026 the US Food and Drug Administration (FDA) approved copper histidinate, a daily injection under the skin, for the treatment of Menkes disease in children — the drug's first approval (Blair 2026). The disease provides the cleanest in vivo demonstration of what happens when all copper-dependent enzymes fail simultaneously.

Back to Table of Contents

Occipital Horn Syndrome (Mild Menkes)

Occipital horn syndrome (OHS) is the milder allelic variant of Menkes disease, caused by ATP7A mutations that retain partial function (typically 5–30% of normal activity). Where classical Menkes is lethal in early childhood, OHS patients survive into adulthood with a connective-tissue-dominant phenotype:

• Occipital exostoses (the "horns") — bilateral bony protrusions from the occipital bone, the eponymous feature, detectable on plain skull radiograph
• Skin laxity — loose, soft skin, particularly on the neck and trunk
• Joint hypermobility — not Marfan-syndrome severity but clinically apparent
• Bladder diverticula — from extracellular matrix weakness in the bladder wall
• Inguinal and umbilical hernias
• Mild cognitive impairment — less severe than classical Menkes
• Arterial tortuosity — visible on angiography

A 1996 report described four related males, aged 4 to 38, with a Menkes variant that combines features of classical Menkes, mild Menkes and OHS. The index patient, an 18-year-old man first evaluated after a brain hemorrhage at age 15, had low muscle tone, developmental delay, bladder diverticula, poor growth and diarrhea from infancy, seizures from age 3, twisted hair (pili torti), loose skin (cutis laxa), multiple joint dislocations, occipital bony growths, hammer-shaped collarbones and twisting brain blood vessels. Blood copper and ceruloplasmin were low, and the family's gene change was predicted to leave about 20% of the normal Menkes gene product. The authors note that such variants can go unrecognised because long survival and later-onset seizures seem inconsistent with Menkes disease (Proud 1996).

OHS was historically classified as "Ehlers-Danlos syndrome type IX" before its molecular cause was identified, reflecting how directly the phenotype mimics other heritable connective-tissue disorders. The current Villefranche Ehlers-Danlos syndrome (EDS) nomenclature has removed type IX, recognizing OHS as a copper-deficiency disorder rather than a primary collagen disorder. The pathophysiologic distinction is moot for clinical purposes — LOX deficiency produces a phenotype that overlaps with collagen-mutation Ehlers-Danlos syndrome because LOX is the cross-linking enzyme that finishes the collagen story.

Back to Table of Contents

Bone Fragility and Cortical Thinning

Copper deficiency produces a characteristic bone phenotype: reduced cortical thickness, metaphyseal flaring, "rib-end" beading mimicking rickets or scurvy, increased fragility, and reduced bone density on a dual-energy X-ray absorptiometry (DEXA) bone-density scan. The mechanism is again primarily lysyl oxidase — the collagen scaffold of bone is the framework on which hydroxyapatite mineral is deposited, and inadequate collagen cross-linking produces a mechanically weaker bone even when mineralization is otherwise normal.

The classic clinical setting is the copper-deficient infant on cow-milk formula (Cordano A et al. 1964) or the long-term TPN patient with inadequate copper. Both groups show characteristic radiographic findings: anterior rib flaring, metaphyseal cupping, osteoporosis with fractures, and "wormian bones" (extra ossification centers in the cranial sutures).

The adult copper-deficiency bone phenotype is less dramatic but still consequential. Population studies suggest a modest association between marginal copper status and reduced bone mineral density and increased fracture risk, particularly in elderly women. Copper status can be measured alongside the conventional Vitamin D, calcium, and parathyroid hormone (PTH) tests used to work up unexplained osteoporosis, fractures beyond what bone density would predict, or a family history of fragility fracture.

Back to Table of Contents

Skin Elasticity, Pili Torti, and Wound Healing

The skin is the most accessible tissue for copper-deficiency assessment, and the hair is among the most sensitive markers. Pili torti — hair shafts twisted around their longitudinal axis, visible on dermoscopy — is the pathognomonic finding of Menkes disease and is also seen in severe acquired copper deficiency. Hair lightening (from tyrosinase failure) is another finding, more subtle in adults than in the strikingly hypopigmented Menkes infant.

Skin laxity, easy bruising, fragile capillaries, and slow wound healing are common in copper deficiency. The mechanism is the same: inadequate collagen and elastin cross-linking produces a dermis that does not maintain its shape under load and does not heal effectively after injury.

The wound-healing application has clinical significance. Surgical patients, burn patients, and patients with chronic wounds (diabetic foot ulcers, pressure ulcers) are at risk if their copper status is marginal. Copper supplementation as part of nutritional support in these settings has demonstrated benefit in observational and small randomized series. Copper supplementation is not standard of care in most wound clinics.

For broader skin-health interventions, see our pages on Acne, Collagen, and the related antioxidant Vitamin C (which is the cofactor for prolyl and lysyl hydroxylase, the enzymes that hydroxylate the collagen precursor before LOX cross-links it — meaning Vitamin C and copper act in series on the same collagen molecules).

Back to Table of Contents

Acquired Vascular Risk in Adults

Beyond the rare genetic conditions, acquired copper deficiency in adults is increasingly recognized as a contributor to vascular pathology. The high-risk populations are:

• Post-bariatric surgery patients — particularly Roux-en-Y gastric bypass and duodenal switch, who bypass the major copper-absorption region of the duodenum and proximal jejunum. The published literature includes case reports of post-bariatric patients presenting with thoracic aortic aneurysm or dissection in the setting of profound copper deficiency, alongside the more familiar copper-deficiency myelopathy. A link between post-bariatric copper deficiency and thoracic aortic aneurysm or dissection has been proposed; the better-documented result is copper-deficiency myelopathy (spinal cord damage), and a history of bariatric surgery is commonly noted in people with it (Kumar 2010).
• Long-term zinc overdose — chronic zinc supplementation above 50 mg/day, denture cream with high zinc content (legacy formulations), or zinc-rich occupational exposure (rare).
• Severe malabsorption — refractory celiac, advanced Crohn's, short-bowel syndrome, chronic pancreatic insufficiency.
• Long-term parenteral nutrition — with inadequate trace mineral supplementation.
• Wilson disease patients on aggressive zinc or chelation therapy — iatrogenic copper deficiency if monitoring lapses.

Human tissue evidence is beginning to appear. A 2022 New Zealand pilot study measured copper in aortic wall tissue taken during heart surgery: tissue from 13 people with a non-inherited (non-syndromic) ascending thoracic aortic aneurysm held less copper (3.34 µg/g dry weight) than tissue from 44 coronary bypass patients without an aneurysm (4.33 µg/g). Copper is scarce in many New Zealand soils, where lime fertilisers make it less available to crops and grazing animals and so to the human food chain; over 46% of the aneurysm patients were Māori living in a copper-deficient region. The authors write that copper deficiency may play a role in these aneurysms and that further studies are needed to establish cause and effect (El-Gamel 2022).

Clinicians who follow these groups describe checking copper, ceruloplasmin, and zinc status periodically (typically every 6–12 months) and keeping copper in the lower-normal to mid-normal range rather than at the lowest acceptable level. Copper supplements are inexpensive, while the vascular damage described on this page can be life-threatening.

Back to Table of Contents

Topical Copper Peptides (GHK-Cu) for Skin

The tripeptide glycyl-L-histidyl-L-lysine (GHK), when complexed with copper as GHK-Cu, has a long history in topical dermatology and wound-care formulations. GHK occurs naturally in human plasma and is thought to act as a copper carrier and a tissue-remodeling signaling peptide. Topical GHK-Cu products have been marketed for anti-aging skincare since the 1980s, and the published in vitro and animal-model literature supports several mechanisms:

• Stimulates collagen and elastin synthesis in cultured fibroblasts
• Activates lysyl oxidase by delivering copper to the active site
• Increases proteoglycan and glycosaminoglycan synthesis in the dermis
• Modulates matrix metalloproteinase activity, favoring tissue remodeling over degradation
• Improves wound healing in animal models of diabetic and pressure ulcers

The human clinical evidence is more limited — small open-label and short-term randomized cosmetic studies of topical GHK-Cu serums show modest improvement in skin firmness, fine wrinkles, and elasticity scores, but rigorous large randomized trials are scarce. The mechanistic basis is plausible (delivering copper transdermally to the dermal fibroblasts that synthesize lysyl oxidase). Topical GHK-Cu acts on the skin; it does not supply the body's copper needs, which come from the diet.

Back to Table of Contents

Key Research Papers

1. Kagan HM, Trackman PC (1991). Properties and function of lysyl oxidase. American Journal of Respiratory Cell and Molecular Biology. — PubMed PMID: 1680355
2. Tinker D, Rucker RB (1985). Role of selected nutrients in synthesis, accumulation, and chemical modification of connective tissue proteins. Physiological Reviews. — PubMed PMID: 2861612
3. Máki JM et al. (2002). Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation. — PubMed PMID: 12417550
4. Kaler SG (2011). ATP7A-related copper transport diseases — emerging concepts and future trends. Nature Reviews Neurology. — PubMed PMID: 21221114
5. Cordano A, Baertl JM, Graham GG (1964). Copper deficiency in infancy. Pediatrics. — PubMed PMID: 14211099
6. Mercer JF (1998). Menkes syndrome and animal models. American Journal of Clinical Nutrition. — PubMed PMID: 9587146
7. Rucker RB et al. (1998). Copper, lysyl oxidase, and extracellular matrix protein cross-linking. American Journal of Clinical Nutrition. — PubMed PMID: 9587142
8. Pickart L, Margolina A (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. — PubMed PMID: 29986520
9. Proud VK, Mussell HG, Kaler SG, Young DW, Percy AK (1996). Distinctive Menkes disease variant with occipital horns: delineation of natural history and clinical phenotype. American Journal of Medical Genetics. — PubMed PMID: 8914740
10. Tinker D, Geller J, Romero N, Cross CE, Rucker RB (1986). Tropoelastin production and tropoelastin messenger RNA activity. Relationship to copper and elastin cross-linking in chick aorta. Biochemical Journal. — PubMed PMID: 2432871
11. Kaler SG, Holmes CS, Goldstein DS, Tang J, Godwin SC, Donsante A, Liew CJ, Sato S, Patronas N (2008). Neonatal diagnosis and treatment of Menkes disease. New England Journal of Medicine. — PubMed PMID: 18256395
12. Blair HA (2026). Copper histidinate: pediatric first approval. Paediatric Drugs. — PubMed PMID: 42018271
13. El-Gamel A, Mak J, Bird S, Grainger MNC, Jacobson GM (2022). Low copper levels measured in the aortic wall of New Zealand patients with non-syndromic ascending thoracic aortic aneurysm. Interactive Cardiovascular and Thoracic Surgery. — PubMed PMID: 36063463
14. Kumar N (2010). Pearls: myelopathy. Seminars in Neurology. — PubMed PMID: 20127580

PubMed Topic Searches

1. PubMed: Lysyl oxidase copper cross-linking
2. PubMed: Copper deficiency and aortic aneurysm
3. PubMed: Menkes disease
4. PubMed: Occipital horn syndrome
5. PubMed: Copper and bone fragility

Back to Table of Contents

Connections

• All Minerals
• Copper Overview
• Copper Benefits Hub
• Beef Liver for Copper & Iron
• Copper for Hemoglobin and Ceruloplasmin
• Copper for Antioxidant Defense
• Copper for Neurological Health
• Zinc (Copper Antagonist)
• Magnesium
• Vitamin C (Collagen Hydroxylation Cofactor)
• Vitamin A
• Collagen
• Organ Meats (Beef Liver)
• Morley Robbins
• Whole Food Copper Sources
• Cardiology
• Dermatology
• Beef
• Dark Chocolate
• Deficiency
• Toxicity
• History
• Sources

Back to Table of Contents

Featured Videos

×